SCS Traditional denied as experimental or investigational by Humana?

Humana's specific coverage criteria for scs traditional are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Traditional SCS as Experimental

Traditional (low-frequency, tonic) spinal cord stimulation has an extensive history of FDA clearance and decades of clinical use for chronic pain conditions including failed back surgery syndrome and complex regional pain syndrome. Nevertheless, Humana may issue an "experimental or investigational" denial if the specific indication, patient population, or device model falls outside what Humana's medical coverage policy identifies as established. This can occur when a device carries a newer FDA clearance, when the indication is an off-label use, or when the submitted diagnosis code does not map to Humana's approved indications list.

## Why This Denial Is Strongly Contestable

An experimental denial for traditional SCS is one of the most facially contestable denial types because the technology itself is long-established. The appeal should demonstrate that (a) the specific device is FDA-cleared for the indicated use, (b) relevant professional societies — including applicable pain medicine, neurosurgery, and neuromodulation organizations — recognize SCS as an established therapy for your diagnosis, and (c) Humana's own coverage policy, read carefully, covers your specific clinical presentation. Independent external reviewers frequently reverse experimental denials for well-established device therapies.

## Your Federal Appeal Rights

• Internal appeal: File under ERISA §503 or Humana's grievance procedures. Request the specific policy provision and the clinical reviewer's rationale used to classify SCS as experimental for your case.
• External review (ACA §2719): Experimental/investigational determinations are a core category of adverse benefit determinations eligible for binding independent external review. Request external review promptly — the window is generally up to four months from denial.
• Expedited review: Available for urgent clinical situations.

## Documentation to Gather

1. FDA clearance documentation — the 510(k) clearance or PMA approval for the specific SCS device, confirming FDA-cleared status for the intended use. 2. Professional society guidance — a statement from your physician referencing the applicable professional society guidelines (e.g., from the North American Neuromodulation Society or applicable pain medicine societies) that recognize SCS for your diagnosis. Do not cite specific statistics — reference the organization and its guidance generically. 3. Diagnosis confirmation — complete diagnostic workup supporting the indication for which SCS is being requested. 4. Prescriber letter — explicit physician attestation that the proposed use is consistent with FDA-cleared indications and established clinical practice, not experimental. 5. Humana policy text — obtain and read Humana's SCS coverage policy carefully; identify whether your diagnosis is listed and whether any experimental exclusion actually applies to traditional (as opposed to newer-modality) SCS.

## Criteria-Mapping Approach

In your appeal, create a section that quotes the experimental/investigational exclusion language from Humana's policy, then directly rebuts it point by point with the FDA clearance document, the professional society reference, and your physician's letter. Request that the internal and external reviewer specifically address why traditional SCS — with its decades of FDA-cleared use — meets Humana's definition of experimental for your specific indication.